Novo Nordisk Weight Loss Pill Shows Promise in Early Trial
• Novo Nordisk stock at record high due to positive trial results for new weight loss pill • New pill could lead to 13% weight loss in 12 weeks, twice as fast as existing injection drug Wegovy • Pill is oral version of drug amycretin, code-named NNC0487-0111; tested on obese Japanese men • Early phase 1 trial still ongoing; larger trials needed to confirm results • Novo Nordisk now 12th most valuable company in the world, surpassing Tesla